Article Information
- Received May 3, 2018
- Revision received August 14, 2018
- Accepted August 21, 2018
- First published August 27, 2018.
- Version of record published October 10, 2018.
Author Information
- Munir Gunes Kutlu1,
- Lillian J. Brady1,
- Emily G. Peck4,
- Rebecca S. Hofford5,
- Jordan T. Yorgason8,
- Cody A. Siciliano4,
- Drew D. Kiraly5,6,7, and
- Erin S. Calipari1,2,3
- 1Department of Pharmacology,
- 2Vanderbilt Center for Addiction Research,
- 3Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,
- 4Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina 07141,
- 5Department of Psychiatry,
- 6Friedman Brain Institute,
- 7Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York 10029, and
- 8Department of Physiology and Developmental Biology, Brigham Young University, Provo, Utah 84602
Author contributions
Author contributions: L.J.B., E.G.P., and J.T.Y. edited the paper; C.A.S., D.D.K., and E.S.C. designed research; L.J.B., C.A.S., D.D.K., and E.S.C. performed research; J.T.Y. contributed unpublished reagents/analytic tools; M.G.K., L.J.B., E.G.P., R.S.H., and E.S.C. analyzed data; M.G.K., D.D.K., and E.S.C. wrote the paper.
Disclosures
- Received May 3, 2018.
- Revision received August 14, 2018.
- Accepted August 21, 2018.
This work was supported by startup funds from the Vanderbilt University School of Medicine (E.S.C.) and the Icahn School of Medicine at Mount Sinai (D.D.K.), the National Institutes of Health, the National Institute of Drug Abuse DA042111(E.S.C.) and DA044308 (D.D.K.), the National Institute of Mental Health MH111216 (C.A.S.), and the Brain and Behavior Research Foundation (E.S.C., D.D.K., and C.A.S.). We thank Erik Oleson for thoughtful comments and support with behavioral economic analysis, and Arthur Godino for input over the course of these studies.
The authors declare no competing financial interests.
- Correspondence should be addressed to either of the following: Dr. Erin S. Calipari, Department of Pharmacology, Vanderbilt Center for Addiction Research, Vanderbilt University School of Medicine, 865F Light Hall, 2215 Garland Avenue, Nashville, TN 37232, erin.calipari{at}vanderbilt.edu; or Dr. Drew D. Kiraly, Department of Psychiatry, Fishberg Department of Neuroscience, Seaver Autism Center for Research and Treatment, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place, New York, NY 10029, drew.kiraly{at}mssm.edu
Other Version
- previous version (August 27, 2018).
- You are viewing the most recent version of this article.
Online Impact